Work

P2.13-08 Phase 1 Study of the AXL Inhibitor DS-1205c in Combination with Osimertinib in Subjects with Metastatic or Unresectable EGFR-Mutant NSCLC.

Year: 2018

Type: article

Source: Journal of Thoracic Oncology

DOI: 10.1016/j.jtho.2018.08.1403

Authors: P. Jänne, H. Yu, N. Shipitofsky, M. Vigliotti, T. Goldberg, J. Li, J. Mcgill, H. Zhang, C. Yu

Institutions: Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Daiichi Sankyo (United States)

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4238075684

FWCI:

Cites:

Cited by:

Related to: 10